Stockreport

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

SCYNEXIS, Inc.  (SCYX) 
Last scynexis, inc. earnings: 11/12 08:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.scynexis.com/investor-relations
PDF JERSEY CITY, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent dif [Read more]